Inovio raises $24M; Did BMS get ZymoGenetics in a steal?;

 @FierceBiotech: "Frustrated" NIH chief plots $1B drug development effort. Story  | Follow @FierceBiotech

 @JohnCFierce: New drug class? Blocking rogue gene stops metastasis. News  | Follow @JohnCFierce

> Inovio Pharmaceuticals is raising $24.3 million from a stock sale to finance the further development of therapeutic and preventive vaccines against cancers and infectious diseases. Inovio release

Xconomy takes a second look at BMS's acquisition of ZymoGenetics, which came just weeks before a big break would make the Seattle biotech worth millions more. Story

And Finally... Researchers at the Biodesign Institute at Arizona State University have been exploring mechanisms of antibody activity to determine if a more thorough understanding of the antibody universe may lead to a new generation of rapid, low-cost diagnostic tools and speed the delivery of new vaccines and therapeutics. Report